Cellyan Biotechnology Co., Ltd (HKPD) Aktienanalyse

Unternehmensübersicht

Cellyan Biotechnology Co., Ltd operates as an investment holding company focused on the over-the-counter pharmaceutical sector within Hong Kong and Mainland China. The firm specializes in cross-border procurement and distribution of OTC pharmaceuticals, alongside providing e-commerce supply chain services and custom solutions for its clients. This entity functions within the Healthcare sector, specifically categorized under the industry of Pharmaceutical Retailers, a segment characterized by the sale of non-prescription medications directly to consumers. The company maintains a market capitalization of $12.04M and reported total revenue of $16.36M over the trailing twelve months, supported by an employee base of 27 individuals. These financial figures indicate that Cellyan Biotechnology is a small-cap enterprise with limited operational scale relative to major pharmaceutical retailers, suggesting a niche market position where revenue generation is constrained by a lean workforce and a specific geographic focus.

Finanzielle Gesundheit

The company recorded revenue of $16.36M for the trailing twelve months, yet reported a net income loss of $-701,880 and an EBITDA figure of $-534,478, highlighting a significant gap between top-line sales and bottom-line profitability. This discrepancy reveals a cost structure where operating expenses substantially exceed gross profits, resulting in a negative net income despite the generation of sales volume. Notably, the company generated free cash flow of $2.44M, which stands in contrast to its negative net income and provides a degree of financial flexibility by indicating that cash conversion from operations is positive despite accounting losses. The balance sheet shows a cash reserve of $2.48M against total debt obligations of $2.27M, while the debt-to-equity ratio stands at 44.19. Although the debt load is nearly equal to cash on hand, the high debt-to-equity ratio suggests a leveraged balance sheet structure rather than a conservative one. Liquidity analysis via the current ratio of 2.93 indicates that the company holds nearly three times the value of current assets relative to its current liabilities, pointing to adequate short-term liquidity to meet immediate obligations. However, return on equity is -13.4% and return on assets is -3.9%, metrics that reveal management has not yet achieved positive capital efficiency or generated returns sufficient to cover the costs of equity and asset deployment.

Bewertungsanalyse

Trailing twelve-month and forward P/E ratios are both listed as N/A, a direct consequence of the company reporting net losses, which precludes the calculation of standard earnings-based valuation multiples. The absence of a positive earnings trajectory implies that traditional earnings-based comparisons are not currently applicable for assessing the company's value relative to profitable peers. The price-to-book ratio is 1.09, indicating that the market values the company at a slight premium of 9% over its book value, suggesting that the market assigns some intangible value to its brand or distribution network despite current losses. Alternative valuation metrics such as a price-to-sales ratio of 0.74 and an EV/EBITDA of -10.15 provide context for the asset's pricing relative to its revenue generation and enterprise value. The 52-week high is $2.76 and the 52-week low is $0.37, establishing a trading range of over seven times in volatility. Without a specific current share price provided in the source data, the position relative to the 52-week high and low cannot be mathematically calculated, though the wide spread suggests significant price discovery or sentiment-driven movement. The beta is listed as N/A, meaning standard volatility metrics relative to the broader market index cannot be determined for this specific security.

Growth & Income

Revenue growth year-over-year declined by 35.7%, while earnings growth year-over-year contracted by 83.1%, indicating that profitability is deteriorating at a significantly faster rate than revenue. This divergence implies that the company is facing increasing cost pressures or a shrinking margin base that is eroding earnings disproportionately to the decline in sales volume. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. As a non-dividend payer, the firm retains its earnings, although currently negative, to fund operations or potentially for future strategic initiatives rather than paying out income to investors. The overall growth and income profile reflects a company in a contractionary phase with no current income distribution mechanism, relying entirely on operational turnaround or external capital to restore profitability and potentially initiate shareholder returns in the future.